Brought to you by 
Investors return for Spiration's seventh round
23 Feb 2009
Executive Summary
Spiration (minimally invasive devices for respiratory diseases) closed an $18.5mm Series G financing from existing shareholders. Lead investor Versant Ventures was joined by Olympus Medical Systems, New Enterprise Associates, New Leaf Venture Partners, InterWest Partners, Investor Growth Capital, and Three Arch Partners. The company will use the funds to complete the clinical testing needed to get its IBV airflow redirection system approved in the US for emphysema; the product already holds the CE Mark in Europe. The Series G money now brings the total invested in Spiration up to $97mm.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investors return for Spiration's seventh round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice